Raltegravir in combination with other antiretroviral agents for the treatment of HIV infection

Raltegravir, an inhibitor of the HIV-1 integrase enzyme, is the first available agent in a new class of antiretroviral drugs. Raltegravir has been studied extensively in clinical trials, and has been well tolerated and highly effective in both treatment-naïve and -experienced patients. Resistance to...

Descripción completa

Detalles Bibliográficos
Autores principales: Chirch, Lisa M, Steigbigel, Roy T
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2010
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3108745/
https://www.ncbi.nlm.nih.gov/pubmed/21694890
_version_ 1782205365718351872
author Chirch, Lisa M
Steigbigel, Roy T
author_facet Chirch, Lisa M
Steigbigel, Roy T
author_sort Chirch, Lisa M
collection PubMed
description Raltegravir, an inhibitor of the HIV-1 integrase enzyme, is the first available agent in a new class of antiretroviral drugs. Raltegravir has been studied extensively in clinical trials, and has been well tolerated and highly effective in both treatment-naïve and -experienced patients. Resistance to raltegravir is unusual given its recent availability, but resistance with identified viral mutation pathways in the integrase gene in patients receiving the drug does occur.
format Online
Article
Text
id pubmed-3108745
institution National Center for Biotechnology Information
language English
publishDate 2010
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-31087452011-06-21 Raltegravir in combination with other antiretroviral agents for the treatment of HIV infection Chirch, Lisa M Steigbigel, Roy T Infect Drug Resist Review Raltegravir, an inhibitor of the HIV-1 integrase enzyme, is the first available agent in a new class of antiretroviral drugs. Raltegravir has been studied extensively in clinical trials, and has been well tolerated and highly effective in both treatment-naïve and -experienced patients. Resistance to raltegravir is unusual given its recent availability, but resistance with identified viral mutation pathways in the integrase gene in patients receiving the drug does occur. Dove Medical Press 2010-04-26 /pmc/articles/PMC3108745/ /pubmed/21694890 Text en © 2010 Chirch and Steigbigel, publisher and licensee Dove Medical Press Ltd. This is an Open Access article which permits unrestricted noncommercial use, provided the original work is properly cited.
spellingShingle Review
Chirch, Lisa M
Steigbigel, Roy T
Raltegravir in combination with other antiretroviral agents for the treatment of HIV infection
title Raltegravir in combination with other antiretroviral agents for the treatment of HIV infection
title_full Raltegravir in combination with other antiretroviral agents for the treatment of HIV infection
title_fullStr Raltegravir in combination with other antiretroviral agents for the treatment of HIV infection
title_full_unstemmed Raltegravir in combination with other antiretroviral agents for the treatment of HIV infection
title_short Raltegravir in combination with other antiretroviral agents for the treatment of HIV infection
title_sort raltegravir in combination with other antiretroviral agents for the treatment of hiv infection
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3108745/
https://www.ncbi.nlm.nih.gov/pubmed/21694890
work_keys_str_mv AT chirchlisam raltegravirincombinationwithotherantiretroviralagentsforthetreatmentofhivinfection
AT steigbigelroyt raltegravirincombinationwithotherantiretroviralagentsforthetreatmentofhivinfection

Ejemplares similares